1. Home
  2. SURG vs PCSA Comparison

SURG vs PCSA Comparison

Compare SURG & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SurgePays Inc.

SURG

SurgePays Inc.

HOLD

Current Price

$0.17

Market Cap

6.4M

ML Signal

HOLD

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.11

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SURG
PCSA
Founded
2006
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.1M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
SURG
PCSA
Price
$0.17
$2.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$25.00
AVG Volume (30 Days)
14.4M
87.5K
Earning Date
04-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
24.69
N/A
EPS
N/A
N/A
Revenue
$56,962,920.00
$5,000.00
Revenue This Year
$136.77
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.11
52 Week High
$3.14
$8.88

Technical Indicators

Market Signals
Indicator
SURG
PCSA
Relative Strength Index (RSI) 35.84 45.24
Support Level $0.15 $2.01
Resistance Level $0.41 $2.38
Average True Range (ATR) 0.04 0.14
MACD -0.00 -0.02
Stochastic Oscillator 8.93 19.12

Price Performance

Historical Comparison
SURG
PCSA

About SURG SurgePays Inc.

Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Share on Social Networks: